HIGHLIGHTS
- who: Narissa Parry from the (UNIVERSITY) have published the research: BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia, in the Journal: (JOURNAL) of 26/04/2022
SUMMARY
BCR::ABL1 confers a survival advantage to CML cells in part through changes to the BCL-2 proteins, particularly through upregulation of BCL-2, MCL-1, and BCL-xL, and downregulation of BIM. BCL-2 prosurvival protein inhibition reduces cell viability and induces apoptosis in BP-CML cell lines IC50 values were determined for BH3 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.